Skip to main content
PMC home page
Gut logoLink to Gut
. 2001 Feb;48(2):272–282. doi: 10.1136/gut.48.2.272

Treatment of irritable bowel syndrome: a review of randomised controlled trials

R AKEHURST 1, E KALTENTHALER 1
PMCID: PMC1728206  PMID: 11156653

Abstract

Irritable bowel syndrome (IBS) is a common chronic disorder that is associated with significant disability and health care costs. The purpose of this paper is to review and assess published randomised controlled trials examining the clinical effectiveness of interventions for IBS for 1987-1998. A literature search was conducted to identify randomised controlled trials of IBS treatments: 45 studies were identified that described randomised controlled trials and of these, six fulfilled all three criteria used to assess the quality of randomised controlled trials, as described by Jadad and colleagues.1 These criteria are: adequate description of randomisation, double blinding, and description of withdrawals and dropouts. It is concluded that there are few studies which offer convincing evidence of effectiveness in treating the IBS symptom complex. This review strongly suggests that future work should include well designed trials that: describe the randomisation method; use internationally approved diagnostic criteria; and are double blinded and placebo controlled. Clear well defined outcome measures are necessary. Inclusion of quality of life measures allows comparison between trials in different therapeutic areas. Conducting such studies will help to overcome some of the difficulties identified in this review.



Full Text

The Full Text of this article is available as a PDF (147.0 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Alevizos B., Christodoulou G. N., Ioannidis C., Voulgari A., Mantidis A., Spiliadis C. The efficacy of amineptine in the treatment of depressive patients with irritable bowel syndrome. Clin Neuropharmacol. 1989;12 (Suppl 2):S66–S76. doi: 10.1097/00002826-198912002-00009. [DOI] [PubMed] [Google Scholar]
  2. Awad R., Dibildox M., Ortiz F. Irritable bowel syndrome treatment using pinaverium bromide as a calcium channel blocker. A randomized double-blind placebo-controlled trial. Acta Gastroenterol Latinoam. 1995;25(3):137–144. [PubMed] [Google Scholar]
  3. Baldi F., Longanesi A., Blasi A., Monello S., Cestari R., Missale G., Corazziari E., Badiali G., Marzio L., Di Felice F. Octylonium bromide in the treatment of the irritable bowel syndrome: a clinical-functional study. Hepatogastroenterology. 1992 Oct;39(5):392–395. [PubMed] [Google Scholar]
  4. Barbier J. P., Dorf G., Gordin J., Krainik F., Neveu D., Parlier H., Richard P., Vitaux J., Fraitag B. Effet de l'association métiodure de buzépide-halopéridol dans le traitement des troubles fonctionnels intestinaux. Etude randomisée en double-aveugle contrôlée contre placebo. Ann Gastroenterol Hepatol (Paris) 1989 May;25(3):123–128. [PubMed] [Google Scholar]
  5. Camilleri M., Choi M. G. Review article: irritable bowel syndrome. Aliment Pharmacol Ther. 1997 Feb;11(1):3–15. doi: 10.1046/j.1365-2036.1997.84256000.x. [DOI] [PubMed] [Google Scholar]
  6. Cann P. A., Rovati L. C., Smart H. L., Spiller R. C., Whorwell P. J. Loxiglumide, a CCK-A antagonist, in irritable bowel syndrome. A pilot multicenter clinical study. Ann N Y Acad Sci. 1994 Mar 23;713:449–450. doi: 10.1111/j.1749-6632.1994.tb44123.x. [DOI] [PubMed] [Google Scholar]
  7. Centonze V., Imbimbo B. P., Campanozzi F., Attolini E., Daniotti S., Albano O. Oral cimetropium bromide, a new antimuscarinic drug, for long-term treatment of irritable bowel syndrome. Am J Gastroenterol. 1988 Nov;83(11):1262–1266. [PubMed] [Google Scholar]
  8. Chapman N. D., Grillage M. G., Mazumder R., Atkinson S. N. A comparison of mebeverine with high-fibre dietary advice and mebeverine plus ispaghula in the treatment of irritable bowel syndrome: an open, prospectively randomised, parallel group study. Br J Clin Pract. 1990 Nov;44(11):461–466. [PubMed] [Google Scholar]
  9. Clouse R. E. Antidepressants for functional gastrointestinal syndromes. Dig Dis Sci. 1994 Nov;39(11):2352–2363. doi: 10.1007/BF02087651. [DOI] [PubMed] [Google Scholar]
  10. Cook I. J., Irvine E. J., Campbell D., Shannon S., Reddy S. N., Collins S. M. Effect of dietary fiber on symptoms and rectosigmoid motility in patients with irritable bowel syndrome. A controlled, crossover study. Gastroenterology. 1990 Jan;98(1):66–72. doi: 10.1016/0016-5085(90)91292-e. [DOI] [PubMed] [Google Scholar]
  11. Dapoigny M., Abitbol J. L., Fraitag B. Efficacy of peripheral kappa agonist fedotozine versus placebo in treatment of irritable bowel syndrome. A multicenter dose-response study. Dig Dis Sci. 1995 Oct;40(10):2244–2249. doi: 10.1007/BF02209014. [DOI] [PubMed] [Google Scholar]
  12. Dobrilla G., Imbimbo B. P., Piazzi L., Bensi G. Longterm treatment of irritable bowel syndrome with cimetropium bromide: a double blind placebo controlled clinical trial. Gut. 1990 Mar;31(3):355–358. doi: 10.1136/gut.31.3.355. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Efskind P. S., Bernklev T., Vatn M. H. A double-blind placebo-controlled trial with loperamide in irritable bowel syndrome. Scand J Gastroenterol. 1996 May;31(5):463–468. doi: 10.3109/00365529609006766. [DOI] [PubMed] [Google Scholar]
  14. Farthing M. J. Irritable bowel, irritable body, or irritable brain? BMJ. 1995 Jan 21;310(6973):171–175. doi: 10.1136/bmj.310.6973.171. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Farup P. G., Hovdenak N., Wetterhus S., Lange O. J., Hovde O., Trondstad R. The symptomatic effect of cisapride in patients with irritable bowel syndrome and constipation. Scand J Gastroenterol. 1998 Feb;33(2):128–131. doi: 10.1080/00365529850166833. [DOI] [PubMed] [Google Scholar]
  16. Gade J., Thorn P. Paraghurt for patients with irritable bowel syndrome. A controlled clinical investigation from general practice. Scand J Prim Health Care. 1989 Mar;7(1):23–26. doi: 10.3109/02813438909103666. [DOI] [PubMed] [Google Scholar]
  17. Goldberg P. A., Kamm M. A., Setti-Carraro P., van der Sijp J. R., Roth C. Modification of visceral sensitivity and pain in irritable bowel syndrome by 5-HT3 antagonism (ondansetron). Digestion. 1996 Nov-Dec;57(6):478–483. doi: 10.1159/000201377. [DOI] [PubMed] [Google Scholar]
  18. Greenbaum D. S., Mayle J. E., Vanegeren L. E., Jerome J. A., Mayor J. W., Greenbaum R. B., Matson R. W., Stein G. E., Dean H. A., Halvorsen N. A. Effects of desipramine on irritable bowel syndrome compared with atropine and placebo. Dig Dis Sci. 1987 Mar;32(3):257–266. doi: 10.1007/BF01297051. [DOI] [PubMed] [Google Scholar]
  19. Halpern G. M., Prindiville T., Blankenburg M., Hsia T., Gershwin M. E. Treatment of irritable bowel syndrome with Lacteol Fort: a randomized, double-blind, cross-over trial. Am J Gastroenterol. 1996 Aug;91(8):1579–1585. [PubMed] [Google Scholar]
  20. Hovdenak N. Loperamide treatment of the irritable bowel syndrome. Scand J Gastroenterol Suppl. 1987;130:81–84. doi: 10.3109/00365528709091004. [DOI] [PubMed] [Google Scholar]
  21. Jadad A. R., Moore R. A., Carroll D., Jenkinson C., Reynolds D. J., Gavaghan D. J., McQuay H. J. Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials. 1996 Feb;17(1):1–12. doi: 10.1016/0197-2456(95)00134-4. [DOI] [PubMed] [Google Scholar]
  22. Lavö B., Stenstam M., Nielsen A. L. Loperamide in treatment of irritable bowel syndrome--a double-blind placebo controlled study. Scand J Gastroenterol Suppl. 1987;130:77–80. doi: 10.3109/00365528709091003. [DOI] [PubMed] [Google Scholar]
  23. Lech Y., Olesen K. M., Hey H., Rask-Pedersen E., Vilien M., Ostergaard O. Behandling af colon irritabile med pebermynteolie. En dobbeltblind undersøgelse med placebo. Ugeskr Laeger. 1988 Oct 3;150(40):2388–2389. [PubMed] [Google Scholar]
  24. Liu J. H., Chen G. H., Yeh H. Z., Huang C. K., Poon S. K. Enteric-coated peppermint-oil capsules in the treatment of irritable bowel syndrome: a prospective, randomized trial. J Gastroenterol. 1997 Dec;32(6):765–768. doi: 10.1007/BF02936952. [DOI] [PubMed] [Google Scholar]
  25. Lucey M. R., Clark M. L., Lowndes J., Dawson A. M. Is bran efficacious in irritable bowel syndrome? A double blind placebo controlled crossover study. Gut. 1987 Feb;28(2):221–225. doi: 10.1136/gut.28.2.221. [DOI] [PMC free article] [PubMed] [Google Scholar]
  26. Lunardi C., Bambara L. M., Biasi D., Cortina P., Peroli P., Nicolis F., Favari F., Pacor M. L. Double-blind cross-over trial of oral sodium cromoglycate in patients with irritable bowel syndrome due to food intolerance. Clin Exp Allergy. 1991 Sep;21(5):569–572. doi: 10.1111/j.1365-2222.1991.tb00848.x. [DOI] [PubMed] [Google Scholar]
  27. Manning A. P., Thompson W. G., Heaton K. W., Morris A. F. Towards positive diagnosis of the irritable bowel. Br Med J. 1978 Sep 2;2(6138):653–654. doi: 10.1136/bmj.2.6138.653. [DOI] [PMC free article] [PubMed] [Google Scholar]
  28. Mathias J. R., Clench M. H., Reeves-Darby V. G., Fox L. M., Hsu P. H., Roberts P. H., Smith L. L., Stiglich N. J. Effect of leuprolide acetate in patients with moderate to severe functional bowel disease. Double-blind, placebo-controlled study. Dig Dis Sci. 1994 Jun;39(6):1155–1162. doi: 10.1007/BF02093778. [DOI] [PubMed] [Google Scholar]
  29. Mathias J. R., Clench M. H., Roberts P. H., Reeves-Darby V. G. Effect of leuprolide acetate in patients with functional bowel disease. Long-term follow-up after double-blind, placebo-controlled study. Dig Dis Sci. 1994 Jun;39(6):1163–1170. doi: 10.1007/BF02093779. [DOI] [PubMed] [Google Scholar]
  30. Maxton D. G., Morris J. A., Whorwell P. J. Ranking of symptoms by patients with the irritable bowel syndrome. BMJ. 1989 Nov 4;299(6708):1138–1138. doi: 10.1136/bmj.299.6708.1138. [DOI] [PMC free article] [PubMed] [Google Scholar]
  31. Maxton D. G., Morris J., Whorwell P. J. Selective 5-hydroxytryptamine antagonism: a role in irritable bowel syndrome and functional dyspepsia? Aliment Pharmacol Ther. 1996 Aug;10(4):595–599. doi: 10.1046/j.1365-2036.1996.30172000.x. [DOI] [PubMed] [Google Scholar]
  32. Misra S. P., Thorat V. K., Sachdev G. K., Anand B. S. Long-term treatment of irritable bowel syndrome: results of a randomized controlled trial. Q J Med. 1989 Oct;73(270):931–939. [PubMed] [Google Scholar]
  33. Moher D., Jadad A. R., Nichol G., Penman M., Tugwell P., Walsh S. Assessing the quality of randomized controlled trials: an annotated bibliography of scales and checklists. Control Clin Trials. 1995 Feb;16(1):62–73. doi: 10.1016/0197-2456(94)00031-w. [DOI] [PubMed] [Google Scholar]
  34. Mollica G., Manno G. L'ottilonio bromuro+diazepam nel trattamento del colon irritabile. Studio controllato versus ottilonio bromuro. Clin Ter. 1992 Aug;141(8):129–134. [PubMed] [Google Scholar]
  35. Nayak A. K., Karnad D. R., Abraham P., Mistry F. P. Metronidazole relieves symptoms in irritable bowel syndrome: the confusion with so-called 'chronic amebiasis'. Indian J Gastroenterol. 1997 Oct;16(4):137–139. [PubMed] [Google Scholar]
  36. Pace F., Coremans G., Dapoigny M., Müller-Lissner S. A., Smout A., Stockbruegger R. W., Whorwell P. J. Therapy of irritable bowel syndrome--an overview. Digestion. 1995;56(5):433–442. doi: 10.1159/000201272. [DOI] [PubMed] [Google Scholar]
  37. Passaretti S., Guslandi M., Imbimbo B. P., Daniotti S., Tittobello A. Effects of cimetropium bromide on gastrointestinal transit time in patients with irritable bowel syndrome. Aliment Pharmacol Ther. 1989 Jun;3(3):267–276. doi: 10.1111/j.1365-2036.1989.tb00213.x. [DOI] [PubMed] [Google Scholar]
  38. Pittler M. H., Ernst E. Peppermint oil for irritable bowel syndrome: a critical review and metaanalysis. Am J Gastroenterol. 1998 Jul;93(7):1131–1135. doi: 10.1111/j.1572-0241.1998.00343.x. [DOI] [PubMed] [Google Scholar]
  39. Poynard T., Naveau S., Mory B., Chaput J. C. Meta-analysis of smooth muscle relaxants in the treatment of irritable bowel syndrome. Aliment Pharmacol Ther. 1994 Oct;8(5):499–510. doi: 10.1111/j.1365-2036.1994.tb00322.x. [DOI] [PubMed] [Google Scholar]
  40. Prior A., Whorwell P. J. Double blind study of ispaghula in irritable bowel syndrome. Gut. 1987 Nov;28(11):1510–1513. doi: 10.1136/gut.28.11.1510. [DOI] [PMC free article] [PubMed] [Google Scholar]
  41. Prior A., Wilson K. M., Whorwell P. J. Double-blind study of an alpha 2 agonist in the treatment of irritable bowel syndrome. Aliment Pharmacol Ther. 1988 Dec;2(6):535–539. doi: 10.1111/j.1365-2036.1988.tb00728.x. [DOI] [PubMed] [Google Scholar]
  42. Rodríguez Magallán A., Valadéz Velázquez T., Llorens Torres F., Sánchez Torres M. I. Tratamiento del colon irritable con lidamidina y psicoterapia de apoyo. Rev Gastroenterol Mex. 1997 Jan-Mar;62(1):7–13. [PubMed] [Google Scholar]
  43. Schäfer E., Ewe K. Behandlung des Colon irritabile. Wirksamkeit und Verträglichkeit von Buscopan plus, Buscopan, Paracetamol und Plazebo bei ambulanten Patienten mit Colon irritabile. Fortschr Med. 1990 Aug 30;108(25):488–492. [PubMed] [Google Scholar]
  44. Schütze K., Brandstätter G., Dragosics B., Judmaier G., Hentschel E. Double-blind study of the effect of cisapride on constipation and abdominal discomfort as components of the irritable bowel syndrome. Aliment Pharmacol Ther. 1997 Apr;11(2):387–394. doi: 10.1046/j.1365-2036.1997.133311000.x. [DOI] [PubMed] [Google Scholar]
  45. Shaw G., Srivastava E. D., Sadlier M., Swann P., James J. Y., Rhodes J. Stress management for irritable bowel syndrome: a controlled trial. Digestion. 1991;50(1):36–42. doi: 10.1159/000200738. [DOI] [PubMed] [Google Scholar]
  46. Snook J., Shepherd H. A. Bran supplementation in the treatment of irritable bowel syndrome. Aliment Pharmacol Ther. 1994 Oct;8(5):511–514. doi: 10.1111/j.1365-2036.1994.tb00323.x. [DOI] [PubMed] [Google Scholar]
  47. Steadman C. J., Talley N. J., Phillips S. F., Zinsmeister A. R. Selective 5-hydroxytryptamine type 3 receptor antagonism with ondansetron as treatment for diarrhea-predominant irritable bowel syndrome: a pilot study. Mayo Clin Proc. 1992 Aug;67(8):732–738. doi: 10.1016/s0025-6196(12)60797-6. [DOI] [PubMed] [Google Scholar]
  48. Tanum L., Malt U. F. A new pharmacologic treatment of functional gastrointestinal disorder. A double-blind placebo-controlled study with mianserin. Scand J Gastroenterol. 1996 Apr;31(4):318–325. doi: 10.3109/00365529609006404. [DOI] [PubMed] [Google Scholar]
  49. Tomás-Ridocci M., Añn R., Mínguez M., Zaragoza A., Ballester J., Benages A. Eficacia del Plantago ovata como regulador del tránsito intestinal. Estudio doble ciego comparativo frente a placebo. Rev Esp Enferm Dig. 1992 Jul;82(1):17–22. [PubMed] [Google Scholar]
  50. Toskes P. P., Connery K. L., Ritchey T. W. Calcium polycarbophil compared with placebo in irritable bowel syndrome. Aliment Pharmacol Ther. 1993 Feb;7(1):87–92. doi: 10.1111/j.1365-2036.1993.tb00074.x. [DOI] [PubMed] [Google Scholar]
  51. Van Outryve M., Mayeur S., Meeus M. A., Rosillon D., Hendrickx B., Ceuppens M. A double-blind crossover comparison study of the safety and efficacy of mebeverine with mebeverine sustained release in the treatment of irritable bowel syndrome. J Clin Pharm Ther. 1995 Oct;20(5):277–282. doi: 10.1111/j.1365-2710.1995.tb00663.x. [DOI] [PubMed] [Google Scholar]
  52. Van Outryve M., Milo R., Toussaint J., Van Eeghem P. "Prokinetic" treatment of constipation-predominant irritable bowel syndrome: a placebo-controlled study of cisapride. J Clin Gastroenterol. 1991 Feb;13(1):49–57. doi: 10.1097/00004836-199102000-00012. [DOI] [PubMed] [Google Scholar]
  53. Villagrasa M., Boix J., Humbert P., Quer J. C. Aleatory clinical study comparing otilonium bromide with a fiber-rich diet in the treatment of irritable bowel syndrome. Ital J Gastroenterol. 1991 Nov;23(8 Suppl 1):67–70. [PubMed] [Google Scholar]

Articles from Gut are provided here courtesy of BMJ Publishing Group

RESOURCES